Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Is Again Defending Avandia

by Lisa M. Jarvis
March 1, 2010 | A version of this story appeared in Volume 88, Issue 9

GlaxoSmithKline is again defending the safety of its diabetes drug Avandia. Last week, a Senate Finance Committee report concluded that GSK knew about the cardiovascular risks of Avandia for years and had tried to intimidate doctors and downplay studies in order to keep the drug on the market. Avandia’s safety was first questioned in 2007 by Steve Nissen, a prominent cardiologist who conducted a meta-analysis of clinical trials and found the drug significantly raised the risk of cardiovascular events. GSK says the scientific evidence does not support the safety concerns and that the Senate report “cherry-picks information.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.